Articles tagged "Kidney transplantation"

2016 American Transplant Congress
Evaluating Delayed Graft Function After Kidney Transplantation as a Potential Surrogate Outcome.
S. Cramm, X. Luo, A. Massie, D. Segev.
Department of Surgery, Johns Hopkins, Baltimore, MD.
Background: Recent work demonstrates significant inter-center heterogeneity in delayed graft function (DGF) rates after kidney transplantation, calling into question the value of a metric based…
2016 American Transplant Congress
The Effect of Everolimus and Tacrolimus Exposure Levels on Renal Histology Parameters 6 Months Post-Transplantation.
S. Yilmaz,¹ D. Shaffer,² Y. Qazi,³ K. McCague,⁴ D. Patel,⁴ V. Peddi,⁵ F. Vincenti.⁶
¹University of Calgary, Calgary, Canada; ²Vanderbilt University, Nashville; ³University of Southern California, Los Angeles; ⁴Novartis Pharmaceuticals Corporation, East Hanover; ⁵California Pacific Medical Center, San Francisco; ⁶University of California San Francisco, San Francisco.
We examined renal histology scores in patients with different exposure levels of everolimus (EVR) and tacrolimus (TAC) over 6 months.Renal transplant patients (N=613) were randomized…
2016 American Transplant Congress
Incidence, Risk Factors, and Outcomes of Delayed Graft Function in Deceased Donor Kidney Transplantation in a Brazilian Center.
A. Ribeiro,¹ M. Helfer,² O. Costa,² A. Viccari,¹ R. Manfro.^1,2
¹Division of Nephrology, Renal Transplant Unit, Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; ²School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Background. A high incidence of delayed graft function (DGF), after deceased donor kidney transplantation, occurs in Brazil and the reasons for such finding have not…
2016 American Transplant Congress
Comparison of Once-Daily and Twice-Daily Low-Dose Tacrolimus in Living Related Kidney Transplantation – Prospective Trial of Once-Daily vs. Twice-Daily Tac – 5 Years Second Report.
T. Tsuchiya, H. Ishida, T. Nozaki, H. Shirakawa, T. Shimizu, K. Omoto, M. Okumi, K. Tanabe.
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Background; Previously, we reported a comparison of the safety and pharmacokinetics between a prolonged-release formulation of Tacrolimus (Tac-QD) and twice-daily tacrolimus (Tac-BD) in the early…
2016 American Transplant Congress
Impediments to Timely Listing for HIV+ Patients Being Evaluated for Kidney Transplantation.
D. Lee,¹ A. Aldea,¹ M. Harhay,² S. Akshay,² G. Malat,³ N. Law,¹ S. DeBellis,² T. Bias,¹ S. Boyle,² K. Ranganna,² A. Doyle.²
¹Division of Infectious Diseases and HIV Medicine, Drexel University, Philadelphia; ²Division of Nephrology, Drexel University, Philadelphia; ³Department of Surgery, Drexel University, Philadelphia.
Introduction:HIV+ individuals can be transplanted safely and effectively but face additional barriers in evaluation and listing.MethodsWe performed a single center chart review of all HIV+…
2016 American Transplant Congress
A Weighted Approach to Composite Efficacy Analysis in Kidney Transplantation.
B. Kaplan, K. MaCague, D. Patel, F. Vincenti.
Mayo Clinic, Phoenix; Novartis Pharmaceuticals Corporation, East Hanover; University of California, San Francisco.
The US92 study determined whether, in de novo renal transplant patients, concentration-controlled everolimus (EVR) with reduced dose tacrolimus (RTAC) is non-inferior to CellCept® (mycophenolate mofetil…
2016 American Transplant Congress
Validation of the Kidney Donor Risk Index (KDRI) in the Australian and New Zealand Kidney Transplant Population.
P. Clayton,^1,2,3 S. White,^1,4 S. McDonald,^1,2,3 S. Chadban.^1,4,5
¹Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, Royal Adelaide Hospital, Adelaide, SA, Australia; ²Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, SA, Australia; ³School of Medicine, University of Adelaide, Adelaide, SA, Australia; ⁴Sydney Medical School, University of Sydney, Sydney, NSW, Australia; ⁵Renal Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Purpose: The kidney donor risk index (KDRI), developed by the United States Scientific Registry of Transplant Recipients (SRTR), was designed to quantify donor kidney quality.…
2016 American Transplant Congress
Soluble ST2 and Cardiovascular (CV) Outcomes and Mortality in Kidney Transplant Candidates.
M. Keddis,¹ Z. El-Zoghby,² A. Gray,² J. Meeusen,² L. Donato,² F. Cosio,² D. Steidley.¹
¹Mayo Clinic, Phoenix, AZ; ²Mayo Clinic, Rochester, MN.
Introduction: Soluble ST2(sST2), involved in T-cell mediated inflammation and cardiac fibrosis, is a better predictor of cardiovascular events(CVE) in heart failure(HF) and is less affected…
2016 American Transplant Congress
The Effect of Tocilizmab Treatment (TCZ-Rx) on IgG Subclasses in HLA-sensitized (HS) Kidney Transplant Patients Treated with TCZ.
B.-H. Shin, S. Ge, J. Choi, J. Kahwaji, A. Vo, A. Petrosyan, S. Jordan, M. Toyoda.
Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Background: Antibody-mediated rejection (ABMR) is a major obstacle for successful transplant in HS patients. TCZ has anti-B cell and anti-inflammatory properties. We have reported its…
2016 American Transplant Congress
Evaluation of Dose Dependent Rabbit Anti-Thymocyte Globulin Induction in Risk-Stratified Kidney Transplant Recipients.
I. Gutman, M. Misel, D. McKay, A. Hemming, J. Kerr, K. Mekeel.
UC San Diego Health System, San Diego, CA.
Background: Rabbit anti-thymocyte globulin (rATG) is a depleting polyclonal antibody often used for induction following kidney transplantation to help prevent acute rejection. The optimal dosage…